BioRestorative Therapies (BRTX) 10-Q 14 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 12, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	1,505,497
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BRTX
Entity Common Stock, Shares Outstanding		2,826,324

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - Entity [Domain] - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current Assets:
Cash	$ 6,445	$ 91,798
Accounts receivable	50,982	0
Inventories	2,492	1,945
Prepaid expenses and other current assets	34,055	20,570
Deferred offering costs	152,167	0
Total Current Assets	246,141	114,313
Property and equipment, net	702,348	493,856
Intangible assets, net	1,076,189	1,037,732
Security deposit	45,900	45,900
Total Assets	2,070,578	1,691,801
Current Liabilities:
Accounts payable	1,746,614	1,111,879
Accrued expenses and other current liabilities	1,887,484	1,466,506
Accrued interest	56,027	94,026
Current portion of notes payable, net of debt discount of $81,366 and $113,257 at June 30, 2015 and December 31, 2014, respectively	1,115,319	5,688,239
Deferred revenues	114,118	164,349
Total Current Liabilities	4,919,562	8,524,999
Accrued interest, non-current portion	1,539	5,195
Notes payable, non-current portion	30,000	50,000
Total Liabilities	$ 4,951,101	$ 8,580,194
Commitments and contingencies
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 5,000,000 shares; none issued and outstanding at June 30, 2015 and December 31, 2014	$ 0	$ 0
Common stock, $0.001 par value; Authorized, 30,000,000 shares; Issued 2,818,363 and 1,725,596 shares at June 30, 2015 and December 31, 2014, respectively; Outstanding 2,790,431 and 1,697,664 shares at June 30, 2015 and December 31, 2014, respectively	2,818	1,726
Additional paid-in capital	25,729,104	18,541,907
Accumulated deficit	(28,580,445)	(25,400,026)
Treasury stock, at cost, 27,932 shares at June 30, 2015 and December 31, 2014	(32,000)	(32,000)
Total Stockholders' Deficiency	(2,880,523)	(6,888,393)
Total Liabilities and Stockholders' Deficiency	$ 2,070,578	$ 1,691,801

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current portion of notes payable, debt discount (in dollars)	$ 81,366	$ 113,257
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, Authorized	5,000,000	5,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, Authorized	30,000,000	30,000,000
Common stock, Issued	2,818,363	1,725,596
Common stock, Outstanding	2,790,431	1,697,664
Treasury stock, at cost, shares	27,932	27,932

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - Entity [Domain] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenues	$ 148,764	$ 175,941	$ 333,666	$ 176,316
Cost of sales	74,645	42,366	151,077	42,426
Gross Profit	74,119	133,575	182,589	133,890
Operating Expenses
Marketing and promotion	49,091	15,535	94,028	47,329
Consulting	138,991	557,565	504,060	824,763
Research and development	452,488	293,330	859,344	787,071
General and administrative	696,353	548,632	1,613,927	1,184,632
Total Operating Expenses	1,336,923	1,415,062	3,071,359	2,843,795
Loss From Operations	(1,262,804)	(1,281,487)	(2,888,770)	(2,709,905)
Other (Expense) Income
Interest expense	(60,096)	(72,390)	(124,736)	(145,521)
Amortization of debt discount	(71,369)	(145,930)	(140,884)	(244,435)
Loss on extinguishment of notes payable, net	(26,029)	0	(26,029)	(49,094)
Warrant modification expense	0	0	0	(30,128)
Gain on settlement of payables	0	166,668	0	176,268
Total Other Expense	(157,494)	(51,652)	(291,649)	(292,910)
Net Loss	$ (1,420,298)	$ (1,333,139)	$ (3,180,419)	$ (3,002,815)
Net Loss Per Share
- Basic and Diluted (in dollars per share)	$ (0.64)	$ (1.17)	$ (1.60)	$ (2.79)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted (in shares)	2,227,400	1,142,606	1,993,544	1,077,606

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficiency) - Class of Stock [Domain] - Related Party [Domain] - 6 months ended Jun. 30, 2015 - USD ($)	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Treasury Stock
Beginning Balance at Dec. 31, 2014	$ (6,888,393)	$ 1,726	$ 18,541,907	$ (25,400,026)	$ (32,000)
Beginning Balance (in shares) at Dec. 31, 2014		1,725,596			(27,932)
Shares and warrants issued for cash	1,051,000	$ 180	1,050,820	0	$ 0
Shares and warrants issued for cash (in shares)		180,167			0
Conversion of notes payable and accrued interest into common stock	170,065	$ 35	170,030	0	$ 0
Conversion of notes payable and accrued interest into common stock (in shares)		34,869			0
Shares issued in satisfaction of accrued services	8,481	$ 1	8,480	0	$ 0
Shares issued in satisfaction of accrued services (in shares)		943			0
Shares and warrants issued in connection with settlement agreement	152,000	$ 4	151,996	0	$ 0
Shares and warrants issued in connection with settlement agreement (in shares)		4,230			0
Warrants issued as debt discount in connection with notes payable	54,415	$ 0	54,415	0	$ 0
Shares and warrants issued in exchange of notes payable	5,142,065	$ 853	5,141,212	0	$ 0
Shares and warrants issued in exchange of notes payable (in shares)		853,360			0
Warrant modifications	15,900	$ 0	15,900	0	$ 0
Beneficial conversion features related to convertible notes payable	10,690	0	10,690	0	0
Stock-based compensation: - common stock	99,147	$ 19	99,128	0	$ 0
Stock-based compensation: - common stock (in shares)		19,198			0
Stock-based compensation: - options	484,526	$ 0	484,526	0	$ 0
Net loss	(3,180,419)	0	0	(3,180,419)	0
Ending Balance at Jun. 30, 2015	$ (2,880,523)	$ 2,818	$ 25,729,104	$ (28,580,445)	$ (32,000)
Ending Balance (in shares) at Jun. 30, 2015		2,818,363			(27,932)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - Entity [Domain] - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows From Operating Activities
Net loss	$ (3,180,419)	$ (3,002,815)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	140,884	244,435
Accretion of interest expense	6,012	0
Depreciation and amortization	89,452	50,139
Loss on sale of property and equipment	0	1,009
Stock-based compensation	583,673	917,792
Loss on extinguishment of note payables, net	26,029	49,094
Gain on settlement of payables	0	(176,268)
Warrant modification expense	10,000	30,128
Changes in operating assets and liabilities:
Accounts receivable	(50,982)	0
Inventories	(547)	175
Prepaid expenses and other current assets	(13,485)	2,648
Accounts payable	313,352	(369,047)
Accrued interest, expenses and other current liabilities	641,873	267,810
Deferred revenues	(50,231)	224,975
Total Adjustments	1,696,030	1,242,890
Net Cash Used In Operating Activities	(1,484,389)	(1,759,925)
Cash Flows From Investing Activities
Purchases of property and equipment	(151,914)	0
Proceeds from sale of property and equipment	0	980
License maintenance costs	(75,000)	0
Net Cash (Used In) Provided By Investing Activities	(226,914)	980
Cash Flows From Financing Activities
Deferred offering costs	(8,050)	0
Proceeds from notes payable	515,000	670,000
Repayments of notes payable	0	(53,000)
Advances from director, officer and family member of officer	274,085	15,015
Repayment of advances from director and officer	(206,085)	(40,005)
Proceeds from exercise of warrants	0	80,000
Sales of common stock and warrants for cash	1,051,000	945,000
Net Cash Provided By Financing Activities	1,625,950	1,617,010
Net Decrease In Cash	(85,353)	(141,935)
Cash - Beginning	91,798	201,098
Cash - Ending	6,445	59,163
Cash paid during the period for:
Interest	46,161	43,821
Non-cash investing and financing activities:
Conversion of notes payable and accrued interest into common stock	170,065	166,768
Accrued interest reclassified as principal in connection with note payable reissuance	0	73,058
Beneficial conversion features set up as debt discount	10,690	41,384
Accrued deferred offering costs	144,117	0
Accrued liabilities associated with purchases of property and equipment	109,487	0
Indebtedness satisfied via legal settlement	5,000	0
Warrant modification in connection with extension or exchanges of notes payable
Non-cash investing and financing activities:
Stock Issued	5,900	0
Shares and warrants issued in connection with issuance or extension of notes payable
Non-cash investing and financing activities:
Stock Issued	54,415	15,000
Shares and warrants issued in exchange for notes payable and accrued interest
Non-cash investing and financing activities:
Stock Issued	5,116,036	343,026
Shares issued in satisfaction of accrued consulting services
Non-cash investing and financing activities:
Stock Issued	8,481	0
Shares and warrants issued in connection with settlement agreement
Non-cash investing and financing activities:
Stock Issued	$ 152,000	$ 0

Business Organization, Nature o

Business Organization, Nature of Operations and Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation Of Financial Statements [Abstract]
Business Organization, Nature of Operations and Basis of Presentation	Note 1 – Business Organization, Nature of Operations and Basis of Presentation BioRestorative Therapies, Inc. (together with its subsidiaries, “BRT” or the “Company”) develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com D I S C www.stempearls.com The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the condensed consolidated financial statements of the Company as of June 30, 2015 and for the three and six months ended June 30, 2015 and 2014. The results of operations for the three and six months ended June 30, 2015 are not necessarily indicative of the operating results for the full year ending December 31, 2015 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2014 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 31, 2015. Effective January 1, 2015, the Company changed its state of incorporation from the State of Nevada to the State of Delaware pursuant to a plan of conversion, dated December 22, 2014 (the “Plan of Conversion”). Pursuant to the Plan of Conversion, the Company also adopted new bylaws, which became effective on January 1, 2015. Effective July 7, 2015, pursuant to authority granted by the stockholders of the Company, the Company implemented a 1-for-20 reverse split of the Company’s issued and outstanding common stock (the “Reverse Split”) and a reduction in the number of shares of common stock authorized to be issued by the Company from 200,000,000 30,000,000

Going Concern and Management Pl

Going Concern and Management Plans	6 Months Ended
	Jun. 30, 2015
Development Stage Enterprise [Abstract]
Going Concern and Management Plans	Note 2 – Going Concern and Management Plans As of June 30, 2015, the Company had a working capital deficiency and a stockholders’ deficiency of $ 4,673,421 2,880,523 1,420,298 3,180,419 The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis and, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to June 30, 2015, the Company has raised an aggregate of $ 180,000 200,000 30,000 1,736 275,000

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and six months ended June 30, 2015. See Revenue Recognition – Research and Development Agreements below. Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On February 11, 2015, the term of the March 19, 2014 research and development agreement with a Japanese pharmaceutical company was extended by three months to June 19, 2015. During the three and six months ended June 30, 2015, the Company recognized revenue of $ 50,000 100,000 200,000 250,000 50,000 During the six months ended June 30, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $ 177,234 605,359 491,241 114,118 During the three and six months ended June 30, 2015, the Company recognized revenue related to research and development agreements of $ 146,764 327,466 175,025 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three and six months ended June 30, 2015, the Company has recognized $ 2,000 6,000 During the three and six months ended June 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 0 200 916 1,291 Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. June 30, 2015 2014 Options 789,200 435,450 Warrants 728,850 316,283 Convertible notes 65,719 74,100 Total potentially dilutive shares 1,583,769 825,833 The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees. The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities June 30, December 31, 2015 2014 (unaudited) Credit card payable $ 3,296 $ 4,739 Accrued payroll 860,253 679,277 Advances from related parties 68,000 - Accrued purchases of property and equipment 54,781 174,801 Accrued research and development expenses 401,175 292,395 Accrued general and administrative expenses 456,077 315,294 Deferred rent 43,902 - Total $ 1,887,484 $ 1,466,506 During the six months ended June 30, 2015, the Company received an aggregate of $ 274,085 206,085 68,000 15,015 aggregate repayments to a director of the Company, an officer of the Company and a family member of an officer of the Company 40,005

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2015
Notes Payable [Abstract]
Notes Payable	Note 5 – Notes Payable Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257) $ 5,738,239 Issuance - 315,000 244,000 - 559,000 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (16,667) (592,874) - (5,020,478) Conversion to equity - (158,333) - - (158,333) Recognition of debt discount - - - (115,005) [1] (115,005) Accretion of interest expense - - - 6,012 [1] 6,012 Amortization of debt discount - - - 140,884 140,884 Outstanding, June 30, 2015 $ - $ 315,000 [2] $ 911,685 $ (81,366) $ 1,145,319 [1] During the six months ended June 30, 2015, a note in the principal amount of $ 244,000 200,000 44,000 [2] As of June 30, 2015, convertible notes with an aggregate principal balance of $ 315,000 75,000 Bermuda Lender On May 11, 2015, Cayman and a lender to Cayman (the “Bermuda Lender”) agreed to extend the maturity date of a note with a principal balance of $ 410,938 316,297 On May 27, 2015, the Company and the Bermuda Lender agreed to exchange five notes (including the note referred to in the above paragraph) with an aggregate principal amount of $ 4,410,937 69,436 746,730 186,682 15.00 672,056 40,000 December 31, 2015 December 31, 2017 5,327 As of June 30, 2015, the Bermuda Lender is a related party as a result of the size of its ownership interest in the Company’s common stock. Convertible Notes and Other Notes Issuances During the six months ended June 30, 2015, the Company issued convertible notes with an aggregate principal balance of $ 315,000 10 12 17,700 10.00 54,415 During the six months ended June 30, 2015, the Company issued a six-month note payable with a principal amount of $244,000 for cash consideration of $200,000. The note bears no interest. The $44,000 difference between the principal amount of the note and the cash received was recorded as debt discount and is being amortized to interest expense over the term of the note. Conversions, Exchanges and Other During the six months ended June 30, 2015, pursuant to the original conversion terms of the convertible notes, the Company elected to convert convertible notes with an aggregate principal balance of $ 158,333 11,732 34,869 4.44 5.16 During the six months ended June 30, 2015, the Company exchanged a convertible note in the principal amount of $ 16,667 827 3,600 504 During the six months ended June 30, 2015, the Company elected to exchange notes payable with an aggregate principal balance of $ 592,874 25,296 103,030 25,756 15.00 92,725 15,249 20,197 During the six months ended June 30, 2015, the contingently adjustable conversion ratio associated with a certain convertible note was resolved. The Company estimated the intrinsic value of the embedded conversion option based upon the difference between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the convertible note. During the three and six months ended June 30, 2015, the Company recognized $ 0 10,690 During the three and six months ended June 30, 2014, the Company recognized $ 41,384

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Operating Lease During the three and six months ended June 30, 2015, the Company recognized approximately $ 29,000 64,000 4,000 14,000 Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. In November 2013, an action was commenced against the Company in the Circuit Court of Palm Beach County, Florida by an alleged former consultant. The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009. 4,230 30,000 7.60 12.00 152,000 The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Employment Agreements On February 9, 2015, the Company hired a President for its Disc/Spine Division (“Division President”) pursuant to an at-will employment agreement which entitles him to a specified salary and a discretionary bonus. In the event the Company terminates the Division President without cause, the Division President is entitled to cash severance payments of $ 150,000 ten 25,000 9.20 three 200,400 On March 9, 2015, the Company and its Chief Executive Officer (“CEO”) agreed to extend the term of his employment agreement to December 31, 2017. Pursuant to the employment agreement, the CEO is entitled to receive a salary of $ 400,000 100,000 300,000 On March 9, 2015, the Company agreed to amend the at-will employment agreement with its Vice President of Research and Development (“VP of R&D”). Pursuant to the employment agreement, as amended, in the event that the VP of R&D’s employment with the Company is terminated without cause, the VP of R&D would currently be entitled to receive a cash severance payment equal to one-half of his base annual salary (such one-half amount currently $ 125,000 Board of Directors On April 6, 2015, the Company elected a new director to replace a director who had previously resigned. Concurrent with the election, the Company granted a ten 15,000 8.00 104,100

Stockholders' Deficiency

Stockholders' Deficiency	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency Authorized Capital On December 19, 2014, effective January 1, 2015, the Company’s shareholders approved the reincorporation of the Company from the State of Nevada to the State of Delaware and in connection therewith (i) approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of common stock authorized to be issued by the Company from 100,000,000 200,000,000 1,000,000 5,000,000 Common Stock and Warrant Offerings During the six months ended June 30, 2015, the Company issued an aggregate of 180,167 5.00 6.00 1,051,000 56,290 188,883 Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to option grants at annual rates ranging from 0 5 Stock Warrants For The Three Months Ended For The Six Months Ended June 30, June 30, 2015 2014 2015 2014 Risk free interest rate 1.32% - 1.71 % 1.55% - 1.74 % 1.22% - 1.71 % 0.39% - 2.20 % Expected term (years) 5.00 5.00 5.00 1.96 - 5.00 Expected volatility 121% - 122 % 120% -129 % 121% - 122 % 120% - 129 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three and six months ended June 30, 2015 was $ 3.76 3.60 3.20 3.80 On May 29, 2015, the Company extended the expiration date of previously outstanding warrants to purchase an aggregate of 5,000 December 31, 2015 December 31, 2017 10,000 The Company recorded stock–based compensation expense of $ 0 0 113,400 167,126 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2014 412,422 $ 17.97 Granted 316,428 13.82 Exercised - - Forfeited - - Outstanding, June 30, 2015 728,850 $ 16.17 3.8 $ 45,500 Exercisable, June 30, 2015 693,850 $ 15.47 3.9 $ 45,500 Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 6.00 32,500 3.9 32,500 7.60 25,000 4.8 25,000 8.00 12,500 4.5 12,500 10.00 56,554 4.6 56,554 10.60 19,000 2.9 19,000 11.60 2,500 4.3 2,500 12.00 5,000 4.8 5,000 15.00 454,638 4.0 454,638 18.80 2,500 4.3 2,500 20.00 27,500 3.9 27,500 30.00 43,140 2.0 43,140 35.00 1,000 1.8 1,000 40.00 6,176 3.4 6,176 50.00 1,000 2.1 1,000 60.00 1,842 2.8 1,842 80.00 3,000 2.3 3,000 Variable [1] 35,000 - - 728,850 3.9 693,850 [1] Warrants to purchase 35,000 30.00 Stock Options For the Three Months Ended For the Six Months Ended June 30, June 30, 2015 2014 2015 2014 Risk free interest rate 1.49 % 1.64% - 2.54 % 1.33% - 1.64 % 1.50% - 2.54 % Expected term (years) 6.00 5.00 - 10.00 5.00 - 6.00 5.00 - 10.00 Expected volatility 121 % 120 % 121% - 122 % 120% - 121 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the options granted during the three and six months ended June 30, 2015 was $ 6.94 7.64 5.00 4.80 See Note 6 – Commitments and Contingencies – Employment Agreements for details associated with the grant of stock options in connection with employment agreements. On January 23, 2015, the Company granted five-year options to consultants to purchase an aggregate of 5,000 9.40 3,750 625 625 39,200 Weighted Average Remaining For the Three Months Ended For The Six Months Ended Unrecognized at Amortization June 30, June 30, June 30, Period 2015 2014 2015 2014 2015 (Years) Consulting $ 21,427 $ 150,962 $ 118,230 $ 251,575 $ 476,246 2.3 Research and development 104,720 32,324 233,152 153,714 643,481 [1] 2.2 General and administrative 63,859 21,280 133,144 104,979 764,074 2.2 $ 190,006 $ 204,566 $ 484,526 $ 510,268 $ 1,883,801 2.2 [1] Includes $ 266,096 Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2014 779,200 $ 12.18 Granted 45,000 8.82 Exercised - - Forfeited (35,000) 6.34 Outstanding, June 30, 2015 789,200 $ 12.25 8.0 $ 317,000 Exercisable, June 30, 2015 365,327 $ 17.49 7.2 $ 28,500 The following table presents information related to stock options at June 30, 2015: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.70 35,000 9.0 15,000 6.40 25,000 - - 6.60 281,250 4.2 3,750 6.80 12,500 - - 7.80 3,000 4.0 3,000 8.00 15,000 - - 9.20 25,000 - - 9.40 5,000 4.6 4,375 10.00 17,250 4.4 17,250 10.60 2,000 8.7 2,000 12.00 49,000 8.3 49,000 13.00 133,750 8.3 92,502 20.00 6,550 7.5 6,550 21.00 113,500 6.6 113,500 22.00 250 2.0 250 24.00 500 0.9 500 25.00 2,150 1.4 2,150 28.00 17,500 4.1 10,500 30.00 45,000 7.4 45,000 789,200 7.2 365,327 Compensatory Common Stock Issuances During the six months ended June 30, 2015, the Company issued an aggregate of 19,198 99,147 943 8,481 For the Three Months Ended For The Six Months Ended Unrecognized at June 30, June 30, June 30, 2015 2014 2015 2014 2015 Consulting $ 22,500 $ 224,500 $ 90,300 $ 234,500 $ - Research and development - 1,827 8,847 5,898 - $ 22,500 $ 226,327 $ 99,147 $ 240,398 $ -

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 8 - Subsequent Events Stock-based Compensation Subsequent to June 30, 2015, the Company issued an aggregate of 6,500 immediately vested Subsequent to June 30, 2015, the Company granted ten-year options to employees and advisors to purchase an aggregate of 19,750 8.75 12,250 7,500 Common Stock and Warrant Offerings Subsequent to June 30, 2015, the Company issued an aggregate of 26,430 6.00 7.00 180,000 22,680 10.00 15.00 24,500 10.00 11.60 50.00 Short Term Advances Subsequent to June 30, 2015, the Company received an aggregate of $ 55,000 Notes Payable On July 7, 2015, pursuant to the provisions of a convertible note with a principal balance of $ 30,000 30,000 1,736 6,490 4.89 On July 9, 2015, the Company issued a convertible note in the principal amount of $ 100,000 10 The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the “ July Note July Note July Note July Note five 3,300 10.00 On July 27, 2015, the Company issued a six-month convertible note in the principal amount of $ 50,000 10 This note and the accrued interest is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to the maturity date and ending on the day immediately prior to the maturity date at a conversion price equal to 65% of the fair market value of the Company’s stock or $3.00 per share five 1,500 10.00 On August 13, 2015, the Company issued a convertible note in the principal amount of $ 60,000 50,000 1

Summary of Significant Accoun15

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Cell Cayman Ltd. (“Cayman”) and Stem Pearls, LLC. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Concentrations and Credit Risk	Concentrations and Credit Risk Two pharmaceutical clients comprised substantially all of the Company’s revenue during the three and six months ended June 30, 2015. See Revenue Recognition – Research and Development Agreements below.
Revenue Recognition	Revenue Recognition Research and Development Agreements The Company’s policy relating to research and development agreements is to recognize research and development revenues associated with such agreements either (a) on a straight-line basis over the term of the agreement, or (b) in accordance with the milestone method of revenue recognition, depending on the nature of the contract terms, subject to potential acceleration upon achievement of contractually specified deliverables. On February 11, 2015, the term of the March 19, 2014 research and development agreement with a Japanese pharmaceutical company was extended by three months to June 19, 2015. During the three and six months ended June 30, 2015, the Company recognized revenue of $ 50,000 100,000 200,000 250,000 50,000 During the six months ended June 30, 2015, in connection with a March 24, 2014 research and development agreement with a U.S. pharmaceutical company, the Company received the third and fourth of four quarterly payments in the aggregate amount of $ 177,234 605,359 491,241 114,118 During the three and six months ended June 30, 2015, the Company recognized revenue related to research and development agreements of $ 146,764 327,466 175,025 Other The Company’s policy is to recognize product sales when the risk of loss and title to the product transfers to the customer, after taking into account potential returns. The Company recognizes sublicensing and royalty revenue when all of the following have occurred: (i) persuasive evidence of an arrangement exists, (ii) the service is completed without further obligation, (iii) the sales price to the customer is fixed or determinable, and (iv) collectability is reasonably assured. During the three and six months ended June 30, 2015, the Company has recognized $ 2,000 6,000 During the three and six months ended June 30, 2015, the Company recognized revenue related to sales of Stem Pearls® skincare products of $ 0 200 916 1,291
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding, plus the impact of common shares, if dilutive, resulting from the exercise of outstanding stock options and warrants, plus the conversion of convertible notes. June 30, 2015 2014 Options 789,200 435,450 Warrants 728,850 316,283 Convertible notes 65,719 74,100 Total potentially dilutive shares 1,583,769 825,833
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Since the shares underlying the Company’s 2010 Equity Participation Plan (the “Plan”) were registered on May 27, 2014, the Company estimates the fair value of the awards granted under the Plan based on the market value of its freely tradable common stock as reported on the OTCQB market. The fair value of the Company’s restricted equity instruments was estimated by management based on observations of the cash sales prices of both restricted shares and freely tradable shares. Awards granted to directors are treated on the same basis as awards granted to employees.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements, except as disclosed in Note 8.

Summary of Significant Accoun16

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Weighted Average Number of Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: June 30, 2015 2014 Options 789,200 435,450 Warrants 728,850 316,283 Convertible notes 65,719 74,100 Total potentially dilutive shares 1,583,769 825,833

Accrued Expenses and Other Cu17

Accrued Expenses and Other Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2015
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: June 30, December 31, 2015 2014 (unaudited) Credit card payable $ 3,296 $ 4,739 Accrued payroll 860,253 679,277 Advances from related parties 68,000 - Accrued purchases of property and equipment 54,781 174,801 Accrued research and development expenses 401,175 292,395 Accrued general and administrative expenses 456,077 315,294 Deferred rent 43,902 - Total $ 1,887,484 $ 1,466,506

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2015
Notes Payable [Abstract]
Notes Payable	Bermuda Lender Convertible Other Debt (defined below) Notes Notes Discount Total Outstanding, December 31, 2014 $ 4,410,937 $ 175,000 $ 1,265,559 $ (113,257) $ 5,738,239 Issuance - 315,000 244,000 - 559,000 Indebtedness satisfied via settlement - - (5,000) - (5,000) Exchanges to equity (4,410,937) (16,667) (592,874) - (5,020,478) Conversion to equity - (158,333) - - (158,333) Recognition of debt discount - - - (115,005) [1] (115,005) Accretion of interest expense - - - 6,012 [1] 6,012 Amortization of debt discount - - - 140,884 140,884 Outstanding, June 30, 2015 $ - $ 315,000 [2] $ 911,685 $ (81,366) $ 1,145,319 [1] During the six months ended June 30, 2015, a note in the principal amount of $ 244,000 200,000 44,000 [2] As of June 30, 2015, convertible notes with an aggregate principal balance of $ 315,000 75,000

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Black-Scholes Option Pricing Model to Warrants Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to warrants granted, the Company used the following weighted average assumptions: For The Three Months Ended For The Six Months Ended June 30, June 30, 2015 2014 2015 2014 Risk free interest rate 1.32% - 1.71 % 1.55% - 1.74 % 1.22% - 1.71 % 0.39% - 2.20 % Expected term (years) 5.00 5.00 5.00 1.96 - 5.00 Expected volatility 121% - 122 % 120% -129 % 121% - 122 % 120% - 129 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Summary of Warrant Activity	A summary of the stock warrant activity during the six months ended June 30, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, December 31, 2014 412,422 $ 17.97 Granted 316,428 13.82 Exercised - - Forfeited - - Outstanding, June 30, 2015 728,850 $ 16.17 3.8 $ 45,500 Exercisable, June 30, 2015 693,850 $ 15.47 3.9 $ 45,500
Information Related to Stock Warrants	The following table presents information related to stock warrants at June 30, 2015: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 6.00 32,500 3.9 32,500 7.60 25,000 4.8 25,000 8.00 12,500 4.5 12,500 10.00 56,554 4.6 56,554 10.60 19,000 2.9 19,000 11.60 2,500 4.3 2,500 12.00 5,000 4.8 5,000 15.00 454,638 4.0 454,638 18.80 2,500 4.3 2,500 20.00 27,500 3.9 27,500 30.00 43,140 2.0 43,140 35.00 1,000 1.8 1,000 40.00 6,176 3.4 6,176 50.00 1,000 2.1 1,000 60.00 1,842 2.8 1,842 80.00 3,000 2.3 3,000 Variable [1] 35,000 - - 728,850 3.9 693,850 [1] Warrants to purchase 35,000 30.00
Black-Scholes Option Pricing Model to Stock Options Granted, Weighted Average Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following weighted average assumptions: For the Three Months Ended For the Six Months Ended June 30, June 30, 2015 2014 2015 2014 Risk free interest rate 1.49 % 1.64% - 2.54 % 1.33% - 1.64 % 1.50% - 2.54 % Expected term (years) 6.00 5.00 - 10.00 5.00 - 6.00 5.00 - 10.00 Expected volatility 121 % 120 % 121% - 122 % 120% - 121 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Stock option expense	The following table presents information related to stock option expense: Weighted Average Remaining For the Three Months Ended For The Six Months Ended Unrecognized at Amortization June 30, June 30, June 30, Period 2015 2014 2015 2014 2015 (Years) Consulting $ 21,427 $ 150,962 $ 118,230 $ 251,575 $ 476,246 2.3 Research and development 104,720 32,324 233,152 153,714 643,481 [1] 2.2 General and administrative 63,859 21,280 133,144 104,979 764,074 2.2 $ 190,006 $ 204,566 $ 484,526 $ 510,268 $ 1,883,801 2.2 [1] Includes $ 266,096
Summary of Option Activity	A summary of the stock option activity during the six months ended June 30, 2015 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, December 31, 2014 779,200 $ 12.18 Granted 45,000 8.82 Exercised - - Forfeited (35,000) 6.34 Outstanding, June 30, 2015 789,200 $ 12.25 8.0 $ 317,000 Exercisable, June 30, 2015 365,327 $ 17.49 7.2 $ 28,500
Information Related to Stock Options	Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 5.70 35,000 9.0 15,000 6.40 25,000 - - 6.60 281,250 4.2 3,750 6.80 12,500 - - 7.80 3,000 4.0 3,000 8.00 15,000 - - 9.20 25,000 - - 9.40 5,000 4.6 4,375 10.00 17,250 4.4 17,250 10.60 2,000 8.7 2,000 12.00 49,000 8.3 49,000 13.00 133,750 8.3 92,502 20.00 6,550 7.5 6,550 21.00 113,500 6.6 113,500 22.00 250 2.0 250 24.00 500 0.9 500 25.00 2,150 1.4 2,150 28.00 17,500 4.1 10,500 30.00 45,000 7.4 45,000 789,200 7.2 365,327
Common Stock Award Expense	The following table presents information related to compensatory common stock expense: For the Three Months Ended For The Six Months Ended Unrecognized at June 30, June 30, June 30, 2015 2014 2015 2014 2015 Consulting $ 22,500 $ 224,500 $ 90,300 $ 234,500 $ - Research and development - 1,827 8,847 5,898 - $ 22,500 $ 226,327 $ 99,147 $ 240,398 $ -

Business Organization and Natur

Business Organization and Nature of Operations - Additional Information (Detail) - shares	Jul. 07, 2015	Jun. 30, 2015	Jan. 02, 2015	Dec. 31, 2014	Dec. 19, 2014
Business Organization and Nature Of Operations [Line Items]
Common stock, authorized		30,000,000	200,000,000	30,000,000	100,000,000
Subsequent Event [Member]
Business Organization and Nature Of Operations [Line Items]
Reverse stock split ratio	the Company implemented a 1-for-20 reverse split
Stockholders equity note, changes in capital structure, retroactive impact	200,000,000 (pre-split) to 30,000,000
Changes in capital structure retroactive impact shares	200,000,000
Common stock, authorized	30,000,000

Going Concern and Management 21

Going Concern and Management Plans - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Working capital deficiency	$ 4,673,421		$ 4,673,421
Stockholders deficiency	(2,880,523)		(2,880,523)		$ (6,888,393)
Net loss	(1,420,298)	$ (1,333,139)	(3,180,419)	$ (3,002,815)
Note principal and accrued interest converted to equity			(5,020,478)
Subsequent Event
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Amount raised through equity financing			180,000
Notes payable aggregate principal past due	$ 275,000		275,000
Proceeds From Debt Financing			200,000
Subsequent Event | Notes Payable, Accrued Interest Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity			1,736
Subsequent Event | Notes Payable, Principal Exchanged
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]
Note principal and accrued interest converted to equity			$ 30,000

Calculation of Weighted Average

Calculation of Weighted Average Dilutive Common Shares (Detail) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	1,583,769	825,833
Options
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	789,200	435,450
Warrants
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	728,850	316,283
Convertible instruments
Exclusion Of Securities [Line Items]
Total potentially dilutive shares	65,719	74,100

Summary of Significant Accoun23

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current	$ 114,118		$ 114,118		$ 164,349
Revenues	148,764	$ 175,941	333,666	$ 176,316
Deferred Revenue, Revenue Recognized			491,241
Revenue Received			605,359
Accounts Receivable, Net, Current	50,982		50,982		$ 0
Sublicense Agreement
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Revenue Recognized	2,000		6,000
Research and development agreements
Summary Of Significant Accounting Policies [Line Items]
Revenues	146,764	175,025	327,466	175,025
Stem Pearls Skincare Products
Summary Of Significant Accounting Policies [Line Items]
Revenues	0	$ 916	200	$ 1,291
Japanese Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue Recognition, Milestone Method, Revenue Recognized	50,000		100,000
Deferred Revenue, Revenue Recognized			250,000
Revenue Received			200,000
Accounts Receivable, Net, Current	50,000		50,000
U.S. Pharmaceutical Company [Member]
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current	114,118		114,118
U.S. Pharmaceutical Company [Member] | Research and Development Agreements Two Year
Summary Of Significant Accounting Policies [Line Items]
Deferred Revenue, Current	$ 177,234		$ 177,234

Accrued Expenses and Other Cu24

Accrued Expenses and Other Current Liabilities (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Credit card payable	$ 3,296	$ 4,739
Accrued payroll	860,253	679,277
Advances from related parties	68,000	0
Accrued purchases of property and equipment	54,781	174,801
Accrued research and development expenses	401,175	292,395
Accrued general and administrative expenses	456,077	315,294
Deferred rent	43,902	0
Total	$ 1,887,484	$ 1,466,506

Accrued Expenses And Other Cu25

Accrued Expenses And Other Current Liabilities - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Accrued Expenses and Other Current Liabilities [Line Items]
Advances from officer	$ 274,085	$ 15,015
Repayment of advances from officer	206,085	$ 40,005
Liability to officer	$ 68,000

Notes Payable (Detail)

Notes Payable (Detail) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Debt Instrument [Line Items]
Outstanding, December 31, 2014				$ 5,738,239
Issuance				559,000
Indebtedness satisfied via settlement				0	$ (53,000)
Exchanges to equity				(5,020,478)
Conversions to equity				(158,333)
Recognition of debt discount				(115,005)
Accretion of interest expense				6,012	0
Amortization of debt discount		$ 71,369	$ 145,930	140,884	$ 244,435
Outstanding, June 30, 2015		1,145,319		1,145,319
Debt Discount
Debt Instrument [Line Items]
Outstanding, December 31, 2014				(113,257)
Issuance				0
Indebtedness satisfied via settlement				0
Exchanges to equity				0
Conversions to equity				0
Recognition of debt discount	[1]			(115,005)
Accretion of interest expense	[1]			6,012
Amortization of debt discount				140,884
Outstanding, June 30, 2015		(81,366)		(81,366)
Bermuda Lender
Debt Instrument [Line Items]
Outstanding, December 31, 2014				4,410,937
Issuance				0
Indebtedness satisfied via settlement				0
Exchanges to equity				(4,410,937)
Conversions to equity				0
Recognition of debt discount				0
Accretion of interest expense				0
Amortization of debt discount				0
Outstanding, June 30, 2015		0		0
Convertible Notes
Debt Instrument [Line Items]
Outstanding, December 31, 2014				175,000
Issuance				315,000
Indebtedness satisfied via settlement				0
Exchanges to equity				(16,667)
Conversions to equity				(158,333)
Recognition of debt discount				0
Accretion of interest expense				0
Amortization of debt discount				0
Outstanding, June 30, 2015	[2]	315,000		315,000
Other Notes
Debt Instrument [Line Items]
Outstanding, December 31, 2014				1,265,559
Issuance				244,000
Indebtedness satisfied via settlement				(5,000)
Exchanges to equity				(592,874)
Conversions to equity				0
Recognition of debt discount				0
Accretion of interest expense				0
Amortization of debt discount				0
Outstanding, June 30, 2015		$ 911,685		$ 911,685
[1]	During the six months ended June 30, 2015, a note in the principal amount of $244,000 bears no interest and was issued for cash consideration of $200,000. The $44,000 difference between the principal amount of the note and the cash received was recorded as debt discount and is being amortized to interest expense over the term of the note.
[2]	As of June 30, 2015, convertible notes with an aggregate principal balance of $315,000 were convertible into shares of common stock at the election of the Company. Of such aggregate principal balance, under certain circumstances, the holder has the right to convert $75,000 in principal into shares of common stock.

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - Line of Credit Facility, Lender [Domain]	1 Months Ended	3 Months Ended			6 Months Ended
	May. 27, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Mar. 31, 2015	Jun. 30, 2014USD ($)	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	May. 29, 2015shares	May. 11, 2015USD ($)
Debt Instrument [Line Items]
Debt instrument, face amount		$ 315,000			$ 315,000
Loss on extinguishment of note payables, net		26,029		$ 0	26,029	$ 49,094
Debt Instrument, Convertible, Beneficial Conversion Feature		0		41,384	10,690	41,384
Amortization Of Debt Discount (Premium)		71,369		145,930	140,884	244,435
Class of Warrant or Right, Outstanding | shares							5,000
Gains (Losses) On Extinguishment Of Debt		(26,029)		$ 0	(26,029)	$ (49,094)
Class Of Warrant Or Rights Expiration Date	Dec. 31, 2017		Dec. 31, 2015
Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Beneficial Conversion Feature					0
Other Notes Payable
Debt Instrument [Line Items]
Debt instrument, face amount		244,000			244,000
Amortization Of Debt Discount (Premium)					44,000
Proceeds from Convertible Debt					200,000
Scenario, Previously Reported [Member]
Debt Instrument [Line Items]
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Grant Date Fair Value		$ 15,249			15,249
In exchange of notes payable
Debt Instrument [Line Items]
Loss on extinguishment of note payables, net					$ 20,197
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		25,756			25,756
Debt Conversion, Original Debt, Amount					$ 592,874
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 15			$ 15
Amortization Of Debt Discount (Premium)					$ 0
Gains (Losses) On Extinguishment Of Debt					$ (20,197)
Debt Conversion, Converted Instrument, Shares Issued | shares					103,030
Accrued Interest Converted Into Stock		$ 25,296			$ 25,296
Warrants and Rights Outstanding		92,725			92,725
In exchange of notes payable | Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount					592,874
Convertible Notes
Debt Instrument [Line Items]
Debt instrument, face amount		315,000			315,000
Loss on extinguishment of note payables, net		$ 504			$ 504
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares		17,700			17,700
Debt Instrument Unamortized Discount		$ 54,415			$ 54,415
Debt Conversion, Original Debt, Amount					$ 158,333
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares		$ 10			$ 10
Amortization Of Debt Discount (Premium)					$ 0
Proceeds from Convertible Debt					75,000
Gains (Losses) On Extinguishment Of Debt		$ (504)			$ (504)
Debt Instrument, Convertible, Terms of Conversion Feature					The convertible notes are convertible into shares of the Company’s common stock during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 62% to 65% of the fair value of the Company’s common stock or (b) $3.00 per share.
Debt Conversion, Converted Instrument, Shares Issued | shares					3,600
Debt Conversion Original Debt Shares Issued | shares					34,869
Original Debt Accrued Interest Converted Into Stock		11,732			$ 11,732
Conversion Debt Accrued Interest Converted Into Stock		$ 827			827
Convertible Notes | Common Stock [Member]
Debt Instrument [Line Items]
Debt Conversion, Original Debt, Amount					$ 16,667
Convertible Notes | Minimum
Debt Instrument [Line Items]
Rate of interest		10.00%			10.00%
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 4.44			$ 4.44
Convertible Notes | Maximum
Debt Instrument [Line Items]
Rate of interest		12.00%			12.00%
Debt Instrument, Convertible, Conversion Price | $ / shares		$ 5.16			$ 5.16
Bermuda Lender
Debt Instrument [Line Items]
Debt instrument, face amount	$ 4,410,937
Loss on extinguishment of note payables, net					$ (5,327)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares	186,682
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 15
Debt Default, Short-term Debt, Amount								$ 316,297
Interest Payable	$ 69,436
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Grant Date Fair Value	$ 672,056
Gains (Losses) On Extinguishment Of Debt					$ 5,327
Bermuda Lender | Common Stock [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Number of Equity Instruments	746,730
Class of Warrant or Right, Outstanding | shares		40,000			40,000
Bermuda Lender | Cayman
Debt Instrument [Line Items]
Aggregate principal amount								$ 410,938

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - Entity [Domain] - Subsequent Event Type [Domain] - Plan Name [Domain] - Equity Component [Domain] - Related Party [Domain] - USD ($)	Apr. 06, 2015	Mar. 09, 2015	Feb. 09, 2015	Nov. 30, 2013	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	May. 29, 2015
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted							45,000
Common stock exercise price							$ 8.82
Loss Contingency, Allegations				The action was associated with an alleged $5,000 loan made in 2009 and an alleged consulting/employment agreement entered into with the Company effective in 2009.
Operating Leases, Rent Expense, Net					$ 29,000	$ 4,000	$ 64,000	$ 14,000
Class of Warrant or Right, Outstanding									5,000
Legal Settlement Agreement [Member]
Commitments and Contingencies Disclosure [Line Items]
Stock Issued During Period, Shares, New Issues							4,230
Class of Warrant or Right, Outstanding					30,000		30,000
Proceeds from Issuance of Warrants							$ 152,000
Legal Settlement Agreement [Member] | Minimum
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 7.60		$ 7.60
Legal Settlement Agreement [Member] | Maximum
Commitments and Contingencies Disclosure [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 12		$ 12
Director
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted	15,000
Common stock exercise price	$ 8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share Based Compensation Arrangement By Share based Payment Award Options Grants In Period Grant Date Fair Value	$ 104,100
Chief Executive Officer
Commitments and Contingencies Disclosure [Line Items]
Salaries, Wages and Officers Compensation, Total		$ 400,000
Deferred Compensation Arrangement with Individual, Description		The CEO is entitled to receive an annual bonus for 2015 equal to 50% of his annual base salary and an annual bonus for the years 2016 and 2017 equal to 50% of his annual base salary in the event certain performance goals, as determined by the Company’s Compensation Committee, are satisfied.
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount		$ 100,000
Division President
Commitments and Contingencies Disclosure [Line Items]
Stock-based compensation, stock option granted			25,000
Common stock exercise price			$ 9.20
Severance Costs			$ 150,000
Share Based Compensation Arrangement By Share Based Payment Award Options Grant Intrinsic Value			$ 200,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Chief Executive Officer Employment Agreements
Commitments and Contingencies Disclosure [Line Items]
Severance Costs		125,000
Deferred Compensation Arrangement with Individual, Cash Award Granted, Amount		$ 300,000

Black-Scholes Option Pricing Mo

Black-Scholes Option Pricing Model to Warrant Granted, Weighted Average Assumptions (Detail) - Warrants	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	5 years	5 years	5 years
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.32%	1.55%	1.22%	0.39%
Expected term (years)				1 year 11 months 16 days
Expected volatility	121.00%	120.00%	121.00%	120.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.71%	1.74%	1.71%	2.20%
Expected term (years)				5 years
Expected volatility	122.00%	129.00%	122.00%	129.00%

Summary of Warrant Activity (De

Summary of Warrant Activity (Detail) - Jun. 30, 2015 - Warrants - USD ($)	Total
Number of Warrants
Beginning Balance	412,422
Granted	316,428
Exercised	0
Forfeited	0
Ending Balance	728,850
Exercisable	693,850
Weighted Average Exercise Price
Beginning Balance	$ 17.97
Granted	13.82
Exercised	0
Forfeited	0
Ending Balance	16.17
Exercisable	$ 15.47
Weighted Average Remaining Life In Years
Outstanding	3 years 9 months 18 days
Exercisable	3 years 10 months 24 days
Aggregate Intrinsic Value
Outstanding	$ 45,500
Exercisable	$ 45,500

Summarized Information Related

Summarized Information Related to Stock Warrants (Detail) - Jun. 30, 2015 - $ / shares		Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants		728,850
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		693,850
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 6
Warrants Outstanding, Number of Warrants		32,500
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		32,500
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 7.60
Warrants Outstanding, Number of Warrants		25,000
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		25,000
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 8
Warrants Outstanding, Number of Warrants		12,500
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 6 months
Warrants Exercisable, Exercisable Number of Warrants		12,500
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 10
Warrants Outstanding, Number of Warrants		56,554
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants		56,554
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 10.60
Warrants Outstanding, Number of Warrants		19,000
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		19,000
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 11.60
Warrants Outstanding, Number of Warrants		2,500
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		2,500
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 12
Warrants Outstanding, Number of Warrants		5,000
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		5,000
Exercise Price 8
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 15
Warrants Outstanding, Number of Warrants		454,638
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years
Warrants Exercisable, Exercisable Number of Warrants		454,638
Exercise Price 9
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 18.80
Warrants Outstanding, Number of Warrants		2,500
Warrants Exercisable, Weighted Average Remaining Life In Years		4 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		2,500
Exercise Price 10
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 20
Warrants Outstanding, Number of Warrants		27,500
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 10 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		27,500
Exercise Price 11
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 30
Warrants Outstanding, Number of Warrants		43,140
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years
Warrants Exercisable, Exercisable Number of Warrants		43,140
Exercise Price 12
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 35
Warrants Outstanding, Number of Warrants		1,000
Warrants Exercisable, Weighted Average Remaining Life In Years		1 year 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		1,000
Exercise Price 13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 40
Warrants Outstanding, Number of Warrants		6,176
Warrants Exercisable, Weighted Average Remaining Life In Years		3 years 4 months 24 days
Warrants Exercisable, Exercisable Number of Warrants		6,176
Exercise Price 14
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 50
Warrants Outstanding, Number of Warrants		1,000
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants		1,000
Exercise Price 15
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 60
Warrants Outstanding, Number of Warrants		1,842
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		1,842
Exercise Price 16
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price		$ 80
Warrants Outstanding, Number of Warrants		3,000
Warrants Exercisable, Weighted Average Remaining Life In Years		2 years 3 months 18 days
Warrants Exercisable, Exercisable Number of Warrants		3,000
Exercise Price 17
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants outstanding, Exercise Price Description	[1]	Variable
Warrants Outstanding, Number of Warrants		35,000
Warrants Exercisable, Weighted Average Remaining Life In Years
Warrants Exercisable, Exercisable Number of Warrants		0
[1]	Warrants to purchase 35,000 shares of common stock have an exercise price which is the greater of $30.00 per share or the fair market value of the common stock on the date certain performance criteria are met. Exercisability of warrants is subject to satisfaction of certain performance criteria which did not occur during the six months ended June 30, 2015.

Black-Scholes Option Pricing 32

Black-Scholes Option Pricing Model to Stock Option Granted, Weighted Average Assumptions (Detail) - Stock Options	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.49%
Expected term (years)	6 years
Expected volatility	121.00%	120.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		1.64%	1.33%	1.50%
Expected term (years)		5 years	5 years	5 years
Expected volatility			121.00%	120.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate		2.54%	1.64%	2.54%
Expected term (years)		10 years	6 years	10 years
Expected volatility			122.00%	121.00%

Information Related to Stock Op

Information Related to Stock Option Expense (Detail) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		$ 22,500	$ 226,327	$ 99,147	$ 240,398
Unrecognized expense		0		0
Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		190,006	204,566	484,526	510,268
Unrecognized expense		1,883,801		$ 1,883,801
Weighted Average Remaining Amortization Period (Years)				2 years 2 months 12 days
Consulting | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		21,427	150,962	$ 118,230	251,575
Unrecognized expense		476,246		$ 476,246
Weighted Average Remaining Amortization Period (Years)				2 years 3 months 18 days
Research and development | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		104,720	32,324	$ 233,152	153,714
Unrecognized expense	[1]	643,481		$ 643,481
Weighted Average Remaining Amortization Period (Years)				2 years 2 months 12 days
General and administrative | Stock Options
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense		63,859	$ 21,280	$ 133,144	$ 104,979
Unrecognized expense		$ 764,074		$ 764,074
Weighted Average Remaining Amortization Period (Years)				2 years 2 months 12 days
[1]	Includes $266,096 of unrecognized expense that is subject to non-employee mark-to-market adjustments.

Summary of Stock Option Activit

Summary of Stock Option Activity (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015
Number of Options
Outstanding	779,200
Granted	45,000
Exercised	0
Forfeited	(35,000)
Outstanding	789,200
Exercisable	365,327
Weighted Average Exercise Price
Outstanding	$ 12.18
Granted	8.82
Exercised	0
Forfeited	6.34
Outstanding	12.25
Exercisable	$ 17.49
Weighted Average Remaining Life In Years
Outstanding	8 years
Exercisable	7 years 2 months 12 days
Intrinsic Value
Outstanding	$ 317,000
Exercisable	$ 28,500

Information Related to Stock 35

Information Related to Stock Options (Detail) - Jun. 30, 2015 - $ / shares	Total
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	789,200
Options Exercisable, Weighted Average Remaining Life In Years	7 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	365,327
Exercise Price 1
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 5.70
Options Outstanding, Outstanding Number of Options	35,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years
Options Exercisable, Exercisable Number of Options	15,000
Exercise Price 2
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 6.40
Options Outstanding, Outstanding Number of Options	25,000
Options Exercisable, Weighted Average Remaining Life In Years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 3
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 6.60
Options Outstanding, Outstanding Number of Options	281,250
Options Exercisable, Weighted Average Remaining Life In Years	4 years 2 months 12 days
Options Exercisable, Exercisable Number of Options	3,750
Exercise Price 4
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 6.80
Options Outstanding, Outstanding Number of Options	12,500
Options Exercisable, Weighted Average Remaining Life In Years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 5
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 7.80
Options Outstanding, Outstanding Number of Options	3,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years
Options Exercisable, Exercisable Number of Options	3,000
Exercise Price 6
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 8
Options Outstanding, Outstanding Number of Options	15,000
Options Exercisable, Weighted Average Remaining Life In Years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 7
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 9.20
Options Outstanding, Outstanding Number of Options	25,000
Options Exercisable, Weighted Average Remaining Life In Years
Options Exercisable, Exercisable Number of Options	0
Exercise Price 8
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 9.40
Options Outstanding, Outstanding Number of Options	5,000
Options Exercisable, Weighted Average Remaining Life In Years	4 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	4,375
Exercise Price 9
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 10
Options Outstanding, Outstanding Number of Options	17,250
Options Exercisable, Weighted Average Remaining Life In Years	4 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	17,250
Exercise price 10
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 10.60
Options Outstanding, Outstanding Number of Options	2,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	2,000
Exercise Price 11
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 12
Options Outstanding, Outstanding Number of Options	49,000
Options Exercisable, Weighted Average Remaining Life In Years	8 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	49,000
Exercise Price 12
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 13
Options Outstanding, Outstanding Number of Options	133,750
Options Exercisable, Weighted Average Remaining Life In Years	8 years 3 months 18 days
Options Exercisable, Exercisable Number of Options	92,502
Exercise Price 13
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 20
Options Outstanding, Outstanding Number of Options	6,550
Options Exercisable, Weighted Average Remaining Life In Years	7 years 6 months
Options Exercisable, Exercisable Number of Options	6,550
Exercise Price 14
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 21
Options Outstanding, Outstanding Number of Options	113,500
Options Exercisable, Weighted Average Remaining Life In Years	6 years 7 months 6 days
Options Exercisable, Exercisable Number of Options	113,500
Exercise Price 15
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 22
Options Outstanding, Outstanding Number of Options	250
Options Exercisable, Weighted Average Remaining Life In Years	2 years
Options Exercisable, Exercisable Number of Options	250
Exercise price 16
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 24
Options Outstanding, Outstanding Number of Options	500
Options Exercisable, Weighted Average Remaining Life In Years	10 months 24 days
Options Exercisable, Exercisable Number of Options	500
Exercise Price 17
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 25
Options Outstanding, Outstanding Number of Options	2,150
Options Exercisable, Weighted Average Remaining Life In Years	1 year 4 months 24 days
Options Exercisable, Exercisable Number of Options	2,150
Exercise Price 18
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 28
Options Outstanding, Outstanding Number of Options	17,500
Options Exercisable, Weighted Average Remaining Life In Years	4 years 1 month 6 days
Options Exercisable, Exercisable Number of Options	10,500
Exercise Price 19
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 30
Options Outstanding, Outstanding Number of Options	45,000
Options Exercisable, Weighted Average Remaining Life In Years	7 years 4 months 24 days
Options Exercisable, Exercisable Number of Options	45,000

Information Related to Common S

Information Related to Common Stock Award Expense (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	$ 22,500	$ 226,327	$ 99,147	$ 240,398
Unrecognized expense	0		0
Consulting | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	22,500	224,500	90,300	234,500
Unrecognized expense	0		0
Research and development | Common Stock Award
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Stock-based compensation expense	0	$ 1,827	8,847	$ 5,898
Unrecognized expense	$ 0		$ 0

Stockholders' Deficiency - Addi

Stockholders' Deficiency - Additional Information (Detail) - Entity [Domain] - Equity Component [Domain] - Subsequent Event Type [Domain] - USD ($)	1 Months Ended		3 Months Ended			6 Months Ended
	May. 29, 2015	Jan. 23, 2015	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Jan. 02, 2015	Dec. 31, 2014	Dec. 19, 2014
Stockholders Equity Note Disclosure [Line Items]
Sales of common stock and warrants for cash						$ 1,051,000	$ 945,000
Stock-based compensation expense			$ 22,500		$ 226,327	$ 99,147	$ 240,398
Share granted vested			625			625
Weighted average estimated fair value of stock options granted			$ 6.94		$ 5	$ 7.64	$ 4.80
Stock-based compensation, stock option granted						45,000
Stock-based compensation, stock options granted, exercise price						$ 8.82
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued						19,198
Grant date fair value						$ 99,147
Common stock, Authorized			30,000,000			30,000,000		200,000,000	30,000,000	100,000,000
Preferred stock, Authorized			5,000,000			5,000,000		5,000,000	5,000,000	1,000,000
Class of Warrant or Right, Outstanding	5,000
Class Of Warrant Or Rights Expiration Date	Dec. 31, 2017			Dec. 31, 2015
Warrant Or Right Expense Or Revenue Recognized			$ 10,000			$ 10,000
Investor
Stockholders Equity Note Disclosure [Line Items]
Class Of Warrant Or Right Term						5 years
Exercise Price Dollor Greaterthan 30.00
Stockholders Equity Note Disclosure [Line Items]
Warrants excluded from computation of weighted average price of warrants granted						35,000
Share based compensation shares authorized under stock option plans exercise price			$ 30			$ 30
Professional Services
Stockholders Equity Note Disclosure [Line Items]
Stock Issued During Period, Shares, Issued for Services						943
Stock Issued During Period, Value, Issued for Services							$ 8,481
Warrants
Stockholders Equity Note Disclosure [Line Items]
Weighted average estimated fair value of stock warrants granted, per share			$ 3.76		$ 3.20	$ 3.60	$ 3.80
Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense			$ 190,006		$ 204,566	$ 484,526	$ 510,268
Consultant Awards | First Anniversary Of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested			3,750			3,750
Consultant Awards | Second Anniversary of Grant Date
Stockholders Equity Note Disclosure [Line Items]
Share granted vested			625			625
Consultant Awards | Employees, Directors and an Advisor
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock option granted		5,000
Stock-based compensation, stock options granted, exercise price		$ 9.40
Consultant Awards | Warrants
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense			$ 0		$ 113,400	$ 0	$ 167,126
Consultant Awards | Non Employee Stock Options
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation expense						266,096
Employee Awards
Stockholders Equity Note Disclosure [Line Items]
Stock-based compensation, stock options granted, grant date fair value						$ 39,200
Equity Participation Plan 2010
Stockholders Equity Note Disclosure [Line Items]
Common stock, Authorized										100,000,000
Common Stock
Stockholders Equity Note Disclosure [Line Items]
Stock issued (in shares)						180,167
Warrants to purchase common stock			56,290			56,290
Warrants aggregate grant date fair value			$ 188,883			$ 188,883
Minimum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price			$ 8			$ 8
Estimated Forfeitures Related To Option Grants Annual Rate						0.00%
Equity Issuance Per Share Value						$ 5
Maximum | Common Stock
Stockholders Equity Note Disclosure [Line Items]
Warrants exercise price			$ 15			$ 15
Estimated Forfeitures Related To Option Grants Annual Rate						5.00%
Equity Issuance Per Share Value						$ 6

Subsequent Events- Additional I

Subsequent Events- Additional Information (Detail) - Entity [Domain] - USD ($)	Aug. 13, 2015	Jul. 27, 2015	Jul. 09, 2015	Jul. 07, 2015	Jun. 30, 2015	May. 29, 2015
Subsequent Event [Line Items]
Warrants Issued During Period, Number of Warrants					19,750
Warrants Issued During Period, Exercise Price					$ 8.75
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross					45,000
Stock Issued During Period, Value, New Issues					$ 1,051,000
Debt Instrument, Face Amount					$ 315,000
Class of Warrant or Right, Outstanding						5,000
Convertible Notes Payable
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					17,700
Debt Instrument, Face Amount					$ 315,000
Proceeds from Convertible Debt					$ 75,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 10
Debt Instrument, Convertible, Terms of Conversion Feature					The convertible notes are convertible into shares of the Company’s common stock during the five days prior to maturity and ending on the day immediately prior to maturity at a conversion price equal to the greater of (a) a range of 62% to 65% of the fair value of the Company’s common stock or (b) $3.00 per share.
Debt Conversion, Original Debt, Amount					$ 158,333
Debt Conversion, Converted Instrument, Shares Issued					3,600
Convertible Notes Payable | Maximum
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 5.16
Convertible Notes Payable | Minimum
Subsequent Event [Line Items]
Debt Instrument, Convertible, Conversion Price					$ 4.44
Subsequent Event
Subsequent Event [Line Items]
Class of Warrant or Right, Outstanding					24,500
Received non-interest bearing advances from officer					$ 55,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 10
Subsequent Event | Maximum
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					50
Subsequent Event | Minimum
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 11.60
Subsequent Event | Consultant
Subsequent Event [Line Items]
Stock Issued During Period, Shares, Issued for Services					6,500
Subsequent Event | Convertible Notes Payable
Subsequent Event [Line Items]
Debt Instrument, Face Amount	$ 60,000		$ 100,000	$ 30,000
Proceeds from Convertible Debt	$ 50,000
Debt Instrument, Interest Rate, Effective Percentage	1.00%		10.00%
Debt Instrument, Convertible, Conversion Price				$ 4.89
Debt Instrument, Convertible, Terms of Conversion Feature	The convertible note is payable as follows: (i) $20,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the “August Note First Maturity Date”), (ii) $20,000 of principal and the respective accrued interest on such principal is payable two weeks following the August Note First Maturity Date, and (iii) $20,000 of principal and the respective accrued interest on such principal is payable one month following the August Note First Maturity Date. Each $20,000 of principal and the respective accrued interest on such principal is convertible into shares of the Company’s common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Company’s stock or (b) $3.00 per share.		The convertible note is payable as follows: (i) $25,000 of the principal and the respective accrued interest on such principal is payable six months from the issuance date (the July NoteFirst Maturity Date), (ii) $25,000 of principal and the respective accrued interest on such principal is payable two weeks following the July Note First Maturity Date, (iii) $25,000 of principal and the respective accrued interest on such principal is payable four weeks following the July Note First Maturity Date and (iv) $25,000 of principal and the respective accrued interest on such principal is payable six weeks following the July Note First Maturity Date. Each $25,000 of principal and the respective accrued interest on such principal is convertible into shares of the Companys common stock at the election of the Company during the period beginning five days prior to each maturity date and ending on the day immediately prior to each maturity date at a conversion price equal to the greater of (a) 62% of the fair value of the Companys stock or (b) $3.00 per share.
Debt Conversion, Original Debt, Amount				$ 30,000
Debt Conversion Original Debt Accrued Interest Amount				$ 1,736
Debt Conversion, Converted Instrument, Shares Issued				6,490
Subsequent Event | Convertible Notes Payable | Lender
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,300
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 10
Warrants Exercisable Term			5 years
Subsequent Event | Six-Month Convertible Note
Subsequent Event [Line Items]
Debt Instrument, Face Amount		$ 50,000
Debt Instrument, Interest Rate, Effective Percentage		10.00%
Debt Instrument, Convertible, Terms of Conversion Feature		5
Subsequent Event | Six-Month Convertible Note | Lender
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		1,500
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 10
Warrants Exercisable Term		5 years
Subsequent Event | Investor
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					22,680
Stock Issued During Period, Shares, New Issues					26,430
Stock Issued During Period, Value, New Issues					$ 180,000
Subsequent Event | Investor | Maximum
Subsequent Event [Line Items]
Sale of Stock, Price Per Share					$ 7
Class of Warrant or Right, Exercise Price of Warrants or Rights					15
Subsequent Event | Investor | Minimum
Subsequent Event [Line Items]
Sale of Stock, Price Per Share					6
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 10
Subsequent Event | Consultants | Immediately Vesting
Subsequent Event [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross					7,500
Subsequent Event | Consultants | Vesting Over Three Months
Subsequent Event [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross					12,250